Department of Gynecologic Surgery, Maternité Jeanne de Flandres, Lille, France
|
|
- Susan Hunter
- 6 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study Michel Cosson, M.D., a Denis Querleu, M.D., a Jacques Donnez, M.D., b Patrick Madelenat, M.D., c Philippe Koninckx, M.D., d Alain Audebert, M.D., e and Hubert Manhes, M.D. f Department of Gynecologic Surgery, Maternité Jeanne de Flandres, Lille, France Received March 20, 2001; revised and accepted December 11, The sponsors of this study, Society Innothera and Schering (France), provided financial and technical support. Reprint requests: Michel Cosson, M.D., Maternité Paul Gelle, 91 Avenue Julien Lagache, Roubaix, France (FAX: ; m- cosson@chru-lille.fr). a Department of Gynecologic Surgery, Maternité Jeanne de Flandres, Lille, France. b Université Catholique de Louvain, Clinique Universitaire St. Luc, Service de Gynécologie Obstétrique, Brussels, Belgium. c Service Gynécologie Obstétrique, Hôpital Bichat-Claude Bernard, Paris, France. d Gasthuisberg University Hospital, Leuven, Belgium. e Centre Hospitalier Bordeaux, Service Gynécologie, Bordeaux, France. f Service Gynécologie Obstétrique, Clinique de la Pergola, Vichy, France /02/$22.00 PII S (01) Objective: To compare the efficacy of Dienogest versus Decapeptyl at 3.75 mg as consolidation therapy for surgery in the treatment of endometriosis. Design: Multicenter, open, randomized, parallel-group clinical trial. Setting: Volunteer patients in an academic research environment. Patient(s): Women with grade 2, 3, and 4 ( 70) endometriosis at initial laparoscopy. Intervention(s): We provided 16 weeks of treatment with Dienogest, 1 mg tablet daily; or with Decapeptyl, 3.75 mg IM injection every 4 weeks. Main Outcome Measure(s): A change in the patient s Revised American Fertility Society score at the post-treatment laparoscopy. Result(s): From June 1994 to July 1998, 142 patients were enrolled in the trial. After exclusion for major protocol deviations, 59 patients were included in the Dienogest group and 61 in the Decapeptyl group. This study group was comparable to the first inclusion group. The patient demographic and clinical characteristics, median duration of endometriosis, Revised American Fertility Society scores, and Visual Analogic Squale (VAS) scores were comparable in both groups. Statistical analysis of efficacy was not significantly different between the two groups. Adverse events were reported by 87.7% of patients in the Dienogest group and 85.1% in the Decapeptyl group. Neither treatment affected patient body weight or vital signs. Conclusion(s): Dienogest is as effective as Decapeptyl for consolidation therapy after surgery for the treatment of endometriosis. The safety profile of dienogest differed from Decapeptyl (3.75 mg). Dienogest constitutes a new therapeutic alternative to the GnRH analogues. (Fertil Steril 2002;77: by American Society for Reproductive Medicine.) Key Words: Randomized trial, endometriosis, GnRH agonist, progestogen Endometriosis is estimated to affect 2% to 3% of the general female population and as many as 15% to 30% of women with primary or secondary infertility (1). In a hypoestrogenic or hyperandrogenic environment, endometriotic implants tend to regress (2, 3). Therefore, several medical antigonadotrophic and antiestrogenic treatments have been developed. Because of their anabolic and androgenic side effects, Danatrol and the progestogens have been replaced by the GnRH analogs (4 7). Recently, progestogens with minimal androgenic activity have been developed (7). There has been no randomized study comparing a progestogen to a GnRH analog for this indication. Dienogest (17 -cyanomethyl-17 -hydroxyestra-4,9-dien-3-one), manufactured by Schering, is a synthetic progestogen derived from 19-norsteroids. Its pharmacologic profile is similar to the progesterone derivatives (17-hydroxy or 19-nor-progesterone). The aim of our study was to compare Dienogest to a GnRH analog as consolidation therapy following operative laparoscopy. The analog we used was 3.75 mg of triptorelin (Decapeptyl ) because of its widespread use, efficacy, and safety (8, 9). 684
2 METHODS This is a phase III, multicenter, open, randomized trial of patients who were found to have stage 2 to 4 endometriosis according to the Revised American Fertility Society (rafs) classification (10) (score 70) and who underwent operative laparoscopy. During a 16-week period, the patients in the study group were prescribed Dienogest, 1 mg orally twice a day. Patients in the control group received an injection of triptorelin, 3.75 mg IM every 4 weeks, for the 16-week period. The efficacy of this postsurgical consolidation treatment was assessed by a clinical examination and a control laparoscopy. Inclusion criteria for this study were patient age of 18 to 40 years, and endometriosis confirmed by diagnostic laparoscopy (Lap.0), irrespective of the initial symptomatology. The rafs 0 scores were 6 to 15 (stage 2), 16 to 40 (stage 3), or 70 (stage 4). Patients must not have had any form of hormonal therapy for a minimum of 3 months prior to enrollment. Patients were excluded if they had any contraindications to laparoscopy or to synthetic progestogens (i.e., past history of thrombophlebitis, myocardial infarction, cerebrovascular accident, hepatitis, diabetes or dyslipidemia, ongoing pregnancy, or uterine hemorrhage of unknown origin). Hormonal treatment within the 3 months preceding diagnostic laparoscopy whether with natural or synthetic estrogens (except local estrogens), Danazol, a GnRH analogue, or combined oral contraceptives (estrogen/progestogen) was not authorized. Patients with prior oral contraceptive use were required have had at least two regular spontaneous cycles prior to the initial laparoscopy. Serious adverse effects were immediately reported to the project manager. Efficacy was assessed after a new clinical examination (change in pain and global patient assessment) and a new laparoscopy (rafs and FOATI endometriosis scores). FOATI is a classification of endometriosis (Ovarian Foci, Tubular Adhesions, Inflammation rating scale) that includes an evaluation of the focus of endometriosis, adhesions, permeability of fallopian tubes, and inflammatory appearance of lesions. Clinical examination and blood tests were also performed to evaluate the safety of the treatments. The run-in procedure comprised three stages (Fig. 1): a clinical stage (V 1 ) to check the inclusion criteria in patients with known or suspected endometriosis, a laparoscopic stage, and a blood test. The laparoscopic stage included a diagnostic stage (Lap.0) to classify and establish a score for the endometriotic lesions according to the rafs (rafs 0) and FOATI (FOATI 0) classifications, and a therapeutic stage (Lap.1). After surgery, a subsequent rafs score (rafs 1) was the reference point before any medical treatment was begun. The blood test verified that there were no biologic exclusion criteria in patients who had met the clinical and laparoscopic inclusion criteria. During the inclusion visit (V 2 ), the patients were given a randomly assigned treatment. Randomization was centralized, with the treatment units numbered from 1 to 8 for each center. The investigator and the patient were only aware of the type of treatment when the decision to enroll the patient was made. Dienogest was supplied in 1-mg film-coated tablets. Decapeptyl was supplied in syringes for IM injections (containing 3.75 mg of triptorelin). The prescriptions were as follows: Dienogest: two 1-mg tablets taken orally every day (i.e., one tablet in the morning and one in the evening) for 16 weeks. Decapeptyl : one 3.75-mg IM injection every 28 days for 16 weeks (i.e., four injections). In the Dienogest group, the treatment was started on the first or the second day of the cycle following laparoscopy. In the Decapeptyl group, the injections were given on an outpatient basis by a state-registered nurse. The first injection of Decapeptyl was given the first or the second day of the cycle after laparoscopy, or from the 24th day of the cycle after laparoscopy according to the investigator (Fig. 2). The global intensity of pain was assessed at V 3 and V 4. A new pelvic examination was performed to detect any modification in the position, sensitivity, mobility, or size of the uterus or the adnexa, pain in the posterior cul-de-sac, or uterosacral nodules. Blood tests checked the lipid profile (total cholesterol, triglycerides, high-density and low-density lipoprotein cholesterol), the fasting blood glucose, serum transaminases (AST, ALT), -GT, and alkaline phosphatase before and after 16 weeks of treatment. When the treatment was discontinued, a control laparoscopy (Lap.2) was performed during the follicular phase of the following spontaneous cycle. The report included a new lesion score, according to the same classifications used at the initial examination (rafs 2 and FOATI 1). After completion of the control laparoscopy, the investigator recorded the global assessment for each patient based on all study data. The reproductive outcome for infertile patients within the 12 months after the end of the medical treatment was recorded. A confidence interval of 90% was calculated to see whether Dienogest and Decapeptyl had at least the same effect. Whether Dienogest was more efficient than Decapeptyl was assessed by calculating a 95% confidence interval and by the level of the bilateral test to detect a difference between the two groups. In our data, efficiency and confidence intervals are reported in such a way that a positive effect means that Dienogest is better than Decapeptyl for a given criterion. The Hodges-Lehmann estimator (11) was used to evaluate the extent of the effect. The 90% and 95% confidence intervals containing the true effect were calculated. The comparison of the lower limit of the 90% confidence interval with the noninferiority threshold, taken to be equal to 4 FERTILITY & STERILITY 685
3 FIGURE 1 Planned interventions and their timing. V 1 run-in visit; Lap.1 diagnostic laparoscopy (rafs 0) (FOATI 0) therapeutic laparoscopy (rafs1); LT1 blood tests (in hospital); V 2 ensure that laboratory tests are normal collection of consent decision to include patient (randomization); D1 first day of menstruation (of cycle following laparoscopy) start of medical treatment; V 3 second month visit; LT2 check laboratory tests (in hospital); V 4 fourth month visit (patient s global assessment); Lap.2 control laparoscopy (rafs 2, FOATI 1) and investigator s global assessment; V 5 visit 12 months after withdrawal of medical treatment (for previously infertile patients). points for the implant scores, allows the noninferiority of Dienogest to Decapeptyl to be evaluated statistically. Thus, if this lower limit is less in absolute terms than 4 points, the noninferiority of Dienogest to Decapeptyl can be concluded significantly at the unilateral 5% level. Analysis for the existence of any difference between the two groups was carried out with the Wilcoxon nonparametric test consistent with the 95% confidence interval containing the true effect. The protocol was approved by the Lille institutional ethics committee and review board on April 5, RESULTS From June 28, 1994, to December 8, 1997, 142 patients were enrolled in 17 centers: 74 in the Dienogest group and 68 in the Decapeptyl group (Fig. 3). Twelve patients withdrew prematurely from the study: nine in the Dienogest group (12.3%) and three in the Decapeptyl group (4.5%). Two patients withdrew from the study before taking any treatment: one patient after being counseled by her general practitioner, the other one because of a spontaneous pregnancy. Five patients withdrew from the study during treatment in the Dienogest group for each of the following reasons: diabetes, metrorrhagia, migraine, gastric pain, and patient s choice. In the Decapeptyl group, one patient withdrew for headache and hot flushes. In the period between the end of the treatment and the control laparoscopy, one patient withdrew for pregnancy and one for hypothyroidism. In the Decapeptyl group, one patient discontinued for a miscarriage. Due to major protocol deviations, 10 patients who were randomized, treated, and for whom a control laparoscopy was performed were excluded (6 patients in the Dienogest group and 4 patients in the Decapeptyl group). Deviations were similar between the two groups. Thus, the remaining 120 patients who were randomized, completed the therapy as prescribed, and underwent a control laparoscopy comprise the population to be analyzed. The mean age and the mean weight were similar in the Dienogest group and the Decapeptyl group (28.5 years 4.9 vs years 5.1, and 58.4 kg 9.9 vs , respectively). The vital signs (systolic blood pressure, diastolic blood pressure, and heart rate) were in the normal range and were comparable between the two groups. Among both groups, 32% of the patients had previously diagnosed 686 Cosson et al. Postoperative treatment of endometriosis Vol. 77, No. 4, April 2002
4 FIGURE 2 Description of treatment. endometriosis, with a median duration of 668 days, which was similar in both groups (Table 1). The majority of these patients had already received a medical (85.7%) or a laparoscopic treatment (80%). The differences between the two groups were not statistically significant. The symptoms and signs were comparable in the Dienogest group and the Decapeptyl group, including pain (83.1% vs. 85.2%) dysmenorrhea (83.6% vs. 91.5%), dyspareunia (66.7% vs. 66.1%), infertility (over half of the patients in both groups), or infertility and pain (approximately 50% in each group). Even though pelvic pain was slightly more common in the Decapeptyl group (67.8% vs. 47.5%, respectively; P.03), its mean duration or intensity was similar in both groups during the menstrual cycle. The total rafs 0 score and each of the components of this score (implant score, adhesion score, posterior cul-de-sac obliteration score) had a similar distribution in the two groups (Table 2). The median implant score (primary efficacy criterion: maximum score of 46) was 20.0 in the Dienogest group and 22.0 in the Decapeptyl group; 25% of patients in each group had an implant score of over 26. The major criterion was the implant score using the rafs classification. The implant and the adhesion score (Table 3) were calculated at the laparoscopies performed in the study: diagnostic laparoscopy at inclusion (Lap.0), postsurgical laparoscopy (Lap.1), and post-treatment control laparoscopy (Lap.2), as shown in Tables 2 through 4. There was no statistically significant difference in the implant scores for the two groups at Lap.2 (P.43). Analysis of the quartiles shows that at least 75% of the patients had a score of less than 16 in the Dienogest group and less than 4 in the Decapeptyl group. No reappearance of implants was observed in at least 25% of the patients in each group (zero score). The median difference of the implant score between the postsurgical laparoscopy and the control laparoscopy (change Lap.2 Lap.1) is identical in the two groups (median: 0). The difference between the changes in the score observed at Lap.2 between the two groups after 4 months of treatment is not statistically significant. The 90% confidence interval shows that the lower limit is 2 while the noninferiority limit was 4. Categorical analysis of change in the implant score (worsening, stability, improvement) revealed no statistically significant difference between the treatments (P.25). More patients had higher adherence score or obliteration of the posterior cul-de-sac at Lap.2 compared to Lap.1 (Table 4). At Lap.2, More patients had also complete FERTILITY & STERILITY 687
5 FIGURE 3 Trial profile. obliteration in the two groups than at Lap.1, but it still remains lower than Lap.0. There was no statistically significant difference between the two groups at Lap.2 (P.85). After 4 months of treatment, the modification in the rafs score for the two groups (score Lap.2 Lap.1) is similar, with no difference observed. The lower limit of the 90% confidence interval is 6. Dienogest is as efficient as Decapeptyl. In the Dienogest group, 34.5% of the patients were very satisfied and 51.7% were satisfied; thus, 86.2% of the patients were satisfied. In the Decapeptyl group 30% of the patients were very satisfied with the treatment, and 50.0% satisfied, thus there was a total of 80.0% satisfied patients. The odds ratios show that the distribution of patients as a function of response in each group is favorable to Dienogest (odds ratio 1.35), but the difference between the two groups is not statistically significant (P.39). In infertile patients before the study, the rate of spontaneous pregnancies was analyzed over 12 months following the end of the treatment (45 patients in the Dienogest group and 41 in the Decapeptyl group). Of these, 15 patients 688 Cosson et al. Postoperative treatment of endometriosis Vol. 77, No. 4, April 2002
6 TABLE 1 Patients with previous endometriosis. Total population (n 35) Dienogest (n 13) Decapeptyl (n 22) Duration of disease (days) Q1; Q3 349; ; ; 1731 Range Prior medical treatment N (%) 30 (85.7) 13 (100.0) 17 (77.3) Prior laparoscopic treatment N (%) 28 (80.0) 12 (92.3) 16 (72.7) (33.3%) in the Dienogest group and 12 patients (29.3%) in the Decapeptyl group had a spontaneous pregnancy, which is not significantly different (P.71) (Table 5). The blood tests showed statistical differences for the following parameters: Total cholesterol: the median increase during treatment was 0.15 g/l (P.01) on Decapeptyl versus 0.05 g/l (P.03) on Dienogest (P intergroup.02). HDL cholesterol: the median increase during treatment was 0.03 g/l on Dienogest (P.04) versus 0.09 g/l on Decapeptyl (P.01). Alkaline phosphatase: the median increase during treatment was 1.0 IU/L (not statistically significant) on Dienogest versus 11 IU/L (P.01) on Decapeptyl (P intergroup.01). At least one side effect was experienced by 92% of the patients, with no difference in frequency between the two groups. Among these, only 23% had a severe side effect. The clinical safety profile of the two treatments was identical, except for spotting being more frequent with Dienogest (61.6% vs. 25.4%), and hot flushes being more frequent with Decapeptyl (61.2% vs. 9.6%). The clinical safety of the treatments was reflected by the global patient satisfaction: 85% of the patients on Dienogest and 80% on Decapeptyl. Dienogest had a good biologic safety, with no changes in blood glucose, and a smaller increase in total cholesterol than Decapeptyl. Finally, alkaline phosphatase was increased with Decapeptyl but not with Dienogest (P intergroup.01). DISCUSSION Progestogens combining a central inhibitory effect with their peripheral action obtain complete resolution of endometriotic lesions in 50% of cases and partial resolution in 13% (12). However, the compounds used (mainly medroxyprogesterone acetate, lynestrenol, ethylnodrel, or norethisterone) have marked adverse metabolic effects (13, 14). The search for more powerful antigonadotropic compounds led to danazol and gestrinone (which has not been marketed). For some time, danazol was the reference therapy for endometriosis, but it had androgenic side effects. GnRH analogs are currently the reference, because they have the same efficacy as danazol, but lack its clinical androgenic and metabolic side effects. This report demonstrates the results of a multicenter, open, randomized, controlled clinical study comparing the efficacy and safety of a progestogen, Dienogest, versus a TABLE 2 Total revised American Fertility Society score. Laparoscopy Dienogest (n 59) (Q1; Q3) Decapeptyl (n 61) (Q1; Q3) Effect 90% CI 95% CI P Lap ; 7 8; ; 61 24; 54 Lap ; 0 2; ; 12 0; 12 Change in score ; 2 10; 4.38 Lap.0 45; 8 44; 20 Lap.1 Lap ; 3 7; ; 40 4; 24 Change in score ; 4 6; 5.97 Lap.2 Lap.1 1; 26 1; 18 FERTILITY & STERILITY 689
7 TABLE 3 Implant score in revised American Fertility Society classification. Laparoscopy Dienogest (n 59) (Q1; Q3) Decapeptyl (n 61) (Q1; Q3) Effect 90% CI 95% CI P Lap ; 5 0; ; 24 16; 26 Lap ; 0 0; ; 4 0; 8 Change in score ; 2 5; 2.47 Lap.1 24; 4 24; 6 Lap.2 Lap ; 0 2; ; 16 0; 4 Change in score ; 0 2; 0.31 Lap.2 Lap.1 0; 4 2; 2 GnRH analog, Decapeptyl, in the treatment of endometriosis. The use of a placebo was not ethically justified, because medical treatments have conclusively demonstrated efficacy in the postoperative management of endometriosis of stages 2 to 4 on the rafs classification (15). Finally, the study was conducted with an open design because of the difference in formulation, the injections, and the issues with creating a double dummy. Having in mind the type of comparison made (i.e., comparison vs. reference therapy), the objective was to demonstrate a comparable efficacy of Dienogest to Decapeptyl. The efficacy of a treatment for endometriosis can be assessed by the anatomic modifications observed in lesions, so laparoscopy was essential before and after treatment. Patients had to be severely affected to justify the second laparoscopy (i.e., stages 2 to 4 on the rafs classification). In these patients, medical treatment was used as an adjunct to surgery. In the literature, the average duration of treatment with GnRH analogs is 6 months. The current trend is to use them for no more than 3 to 4 months, as they have harmful effects on bone metabolism. Because 3 months is a relatively short period of time to assess the therapeutic effect of a progestogen, 4 months seemed to be a good compromise. The anatomic criteria (scores recorded at laparoscopy) are the TABLE 4 Adhesion score in revised American Fertility Society classification. Laparoscopy Dienogest (n 59) (Q1; Q3) Decapeptyl (n 61) (Q1; Q3) Effect 90% CI 95% CI P Lap ; 1 4; ; 22 4; 16 Lap ; 0 0; ; 4 0; 0 Change in score ; 2 3; 3.83 Lap.1 17; 1 16; 2 Lap.2 Lap ; 4 1; ; 16 2; 16 Change in score ; 4 0; 4.15 Lap.2 Lap.1 0; 2 1; Cosson et al. Postoperative treatment of endometriosis Vol. 77, No. 4, April 2002
8 TABLE 5 Pregnancy rate and characteristics of the spontaneous pregnancies. Pregnancies Dienogest (n 45) Decapeptyl (n 41) n % n % Total spontaneous pregnancies a Proceeding normally to term Conception after treatment Conception during treatment Interrupted pregnancies Conception after treatment Conception during treatment a P.71. only objective criteria to evaluate the evolution of the disease. The modification in the rafs score (difference between rafs 2 and rafs 1 obtained after the surgical cure) was the first criterion defined in the protocol. This score evaluates the posterior cul-de-sac obliteration, implant and adhesion scores; the efficacy of the medical treatment was best assessed with the implant score, which is the most specific criterion, so it was used as the main criterion during the study. There was no significant difference in implants or adhesions, tubal or ovarian localization, or changes in the global score or the score for each individual type of lesion related to the population evaluated. These results show that Dienogest is as effective as Decapeptyl. Moreover, both treatments are equivalent in terms of efficacy, the effect observed being zero and not statistically significant (P.31). This noninferiority of Dienogest was also apparent in patients with severe disease (implant score 15 at diagnostic laparoscopy), taking account of the date of the post-treatment laparoscopy. According to Evers (16), the scores recorded after the return of menstruation are the most relevant. A comparison between endometriosis status (implants and adhesions) before and after medical treatment shows an improved global score in 20% of patients in both groups. No change was observed in 53% of the patients treated with Dienogest or in 60% of those treated with Decapeptyl. Therefore, we can conclude that in both groups results were satisfactory in 70% to 80% of cases, which is equivalent to the results previously observed with Danazol in both comparative (17) and placebo-controlled (13) studies. This is similar to the success rate observed with Decapeptyl (8, 9) and other GnRH analogs tested in the treatment of endometriosis (18). Furthermore, there was no statistically significant difference between the two groups regarding the inflammatory status as assessed by the FOATI score. The reduction in pain was the same with both treatments. Among the patients, 86 were complaining of infertility (45 in the Dienogest group and 41 in the Decapeptyl group). In the Dienogest group, the pregnancy rate was 33%, and 13 out of the 15 pregnant patients delivered. In the Decapeptyl group, 29% of the patients became pregnant, and 9 out of 12 delivered. The total rate of deliveries was 29% on Dienogest versus 22% on Decapeptyl. The difference between the two groups favored Dienogest, but was not statistically significant. In cases of infertility, Dienogest is not inferior to Decapeptyl, with no increased risk of infertility or miscarriage. With regard to clinical safety, the symptoms in treated patients mainly involved the automatic nervous system. Because GnRH analogs induce a chemical menopause, the climacteric syndrome is usual. Hot flushes were reported in 61% of women treated with the GnRH analog (severe in 31%), compared with 11% of women treated with progestogen. Vaginal bleeding was most common complication observed with Dienogest (61.6% of cases as compared with 25.4% of those treated with the GnRH analog). Bleeding usually was no more than spotting, which is a common problem during the first months after hormone therapy (hormone replacement therapy or oral contraception, particularly at low doses). The treatments were well tolerated, as shown by the global satisfaction rate. On the other hand, and unlike the situation observed in patients treated with classic progestogens or danazol, there were no reports of significant androgenic effects such as weight gain, acne, alopecia, or virilism (hirsutism). This confirms the previous reports that Dienogest is not androgenic (19). The overall safety and efficacy of these treatments from the point of view of the patients and the physicians were assessed by recording a global satisfactory rate: 85.5% of the patients treated with Dienogest and 80% of those treated with Decapeptyl were satisfied or very satisfied. Dienogest had no androgenic effects and this was confirmed at the biologic level. The main biochemical modification was an FERTILITY & STERILITY 691
9 increase in alkaline phosphatase in the Decapeptyl group, which may reflect an increased bone turnover. This was not seen with Dienogest. The lipid profile (particularly HDL cholesterol) and blood glucose levels were similar in both groups. CONCLUSION Dienogest is a therapeutic alternative to GnRH analogs in the treatment of endometriosis. In this study, a 4-month postoperative treatment of endometriosis with Dienogest was as efficient as Decapeptyl and had no androgenic effects. Acknowledgments: The authors thank Dr. Pennehouat (Paris, France), Dr. Cusumano (Liège, Belgium), Dr. Pettemans (Brussels, Belgium), Pr. Tran (Nice, France), and Pr. Raudrant (Lyon, France) for help in the investigation; and also Afchine Fazel, M.D., and Yukio Sonoda, M.D., for their essential editorial help. References 1. Muse KN, Wilson EA. How does mild endometriosis cause infertility? Fertil Steril 1982;38: Bur ME, Greene GL, Press MF. Estrogen receptor localization in formalin-fixed paraffin embedded endometrium and endometriotic tissues. Int J Gynecol Pathol 1987;6: Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Gynecol 1992;166: Donnez J, Nisolle M, Grandjean P, Gillerot S, Clerckx F. La place des agonistes de la GnRH dans le traitement par voies endoscopiques de l endométriose et des fibromyomes. Contracep Fertil Sex 1993;21: Henzl MR, Cordon SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med 1998;318: Wheeler JM, Knittle JD. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. Efficacy results. Am J Obstet Gynecol 1992;167: Dorangeon P, Buvat-Herbaut M, Buvat J, Thomas JL. Traitement de l endométriose par l acétate de nomégestrol. Gynecologie 1993;1: Meldrum DR, Chang RJ, Lu J, Valt W, Rivier J, Judd HL. Medical oophorectomy using a long-acting GnRH agonist a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab 1982;54: Zorn JR, Tanger C, Roger M, Grenier J, Comaru-Schally AM, Schally AV. Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Tr-6-luteinizing hormone releasing hormone: a preliminary study in eight women with endometriosis. Int J Fertil 1986;31: The American Fertility Society. Revised American Fertility Society classification of endometriosis, Fertil Steril 1985;43: Hodges JL, Lehmann EL. Estimates of location based on rank tests. Ann Math Stat 1963;34: Bruhat MA, Canis M. Diagnostic et traitement actuel de l endométriose externe. Contracep Fertil Sex 1986;14: Telimaa S, Ronnberg L, Kauppila A. A placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in treatment of endometriosis after comparative surgery. Gynecol Endocrinol 1987;1: Acosta AA. Medical treatment of endometriosis. In: Hedon B, Bringer J, Mares P, eds. Proceedings of the 15th World Congress on Fertility and Sterility, Montpellier, France, September 17 22, New York: Parthenon, 1995: Hornsteins MD, Hemmings R, Yuzpe AA, Heinrichs WL. Use of nafarelin versus placebo after reductive laparoscopy surgery of endometriosis. Fertil Steril 1997;68: Evers JLH. Endometriosis does not exist; all women have endometriosis. Hum Reprod 1994;9: Barbieri RL, Evans S, Kister RW. Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril 1982;37: Lemay A, Maheux R, Huot C, Blanchet J, Faure N. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol 1988;158: Kohler G, Brackmann K. Modification des paramètres du métabolisme lipidique sous traitement de l endométriose par dienogest. N Klin Med 1987;42: Cosson et al. Postoperative treatment of endometriosis Vol. 77, No. 4, April 2002
Palm Beach Obstetrics & Gynecology, PA
Palm Beach Obstetrics & Gynecology, PA 4671 S. Congress Avenue, Lake Worth, FL 33461 561.434.0111 4631 N. Congress Avenue, Suite 102, West Palm Beach, FL 33407 Endometriosis The lining of the uterus is
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationBuserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study*
.. FERTILITY AND STERILITY Copyright 99 The American Fertility Society Vol. 59, No., March 99 Printed on acid-free paper in U.S.A. Buserelin acetate in the treatment of pelvic pain associated with minimal
More informationKey Words: Endometriosis, GnRH-a, goserelin, Zoladex, estrogen, sex-steroid add-back therapy,
FERTLTY AND STERLTY Copyright 1995 American Society for Reproductive Medicine Vol. 64, No. 5, November 1995 Printed on acid free paper in U. S. A. Comparison of the gonadotropin-releasing hormone agonist
More informationThe Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage
The Use of GnRH Agonists in the Treatment of Endometriomas With or Without Drainage Pages with reference to book, From 30 To 32 Sertac Batioglu, Havva Celikkanat, Mustafa Ugur, Leyla Mollamahmutoglu, Huseyin
More informationResults of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A.
Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A. Ott's Research Institute of Obstetrics, Gynecology and Reproductology,
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationEndometriosis. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax
Endometriosis What you need to know 139 Dumaresq Street Campbelltown Phone 4628 5292 Fax 4628 0349 www.nureva.com.au September 2015 What is Endometriosis? Endometriosis is a condition whereby the lining
More informationAn evidence-based medicine approach to the treatment of endometriosis-associated chronic pelvic pain: placebo-controlled studies Howard F M
An evidence-based medicine approach to the treatment of endometriosis-associated chronic pelvic pain: placebo-controlled studies Howard F M Authors' objectives To assess the efficacy of treatment of endometriosis-associated
More informationCliniques Universitaires St. Luc, Université Cathologique de Louvain, Brussels, Belgium
FERTILITY AND STERILITY VOL. 81, NO. 2, FEBRUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Equivalence of the 3-month
More informationInternational Journal of Gynecology and Obstetrics
International Journal of Gynecology and Obstetrics 108 (2010) 21 25 Contents lists available at ScienceDirect International Journal of Gynecology and Obstetrics journal homepage: www.elsevier.com/locate/ijgo
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationNeodymium: VAG laser hysteroscopy in large submucous fibroids
FERTILITY AND STERILITY Copyright 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Neodymium: VAG laser hysteroscopy in large submucous fibroids Jacques Donnez, M.D., Ph.D.*
More informationMANAGEMENT OF REFRACTORY ENDOMETRIOSIS
(339) MANAGEMENT OF REFRACTORY ENDOMETRIOSIS Serdar Bulun, MD JJ Sciarra Professor and Chair Department of Ob/Gyn Northwestern University ENDOMETRIOSIS OCs Teenager: severe dysmenorrhea often starting
More informationEndometriosis Treatment & Management Medscape
Endometriosis Treatment & Management Medscape Updated: Apr 25, 2016 Author: G Willy Davila, MD; Chief Editor: Michel E Rivlin, MD more... Approach Considerations The dependence of endometriosis on the
More informationGoserelin (Zoladex*) depot in the treatment of endometriosist
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Goserelin (Zoladex*) depot in the treatment of endometriosist Romeo P. Reichel, M.D.* Karl-W.
More informationCritical Appraisal of Endometriosis Management for Pain and Subfertility
Critical Appraisal of Endometriosis Management for Pain and Subfertility N. F. Zuberi,J. H. Rizvi ( Department of Obstetrics and Gynaecology, The Aga Khan University, Karachi. ) Introduction Endometriosis
More informationIs the endometriosis recurrence rate increased after ovarian hyperstimulation?
Is the endometriosis recurrence rate increased after ovarian hyperstimulation? Thomas M. D Hooghe, M.D., Ph.D., Bénédicte Denys, M.D., Carl Spiessens, Ph.D., Christel Meuleman, M.D., and Sophie Debrock,
More informationORILISSA (elagolix) oral tablet
ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationThis case represents 1 of the challenges of
OBG MANAGEMENT BY DAVID ADAMSON, MD Minimal to mild endometriosis: 4 treatment options Since even limited disease can cause infertility or substantial pain, it should be taken as seriously as severe endometriosis.
More informationEndometriosis. *Chocolate cyst in the ovary
Endometriosis What is endometriosis? Endometriosis is a common condition in young women. It's chronic, painful, and it often progressively gets worse over the time. *Chocolate cyst in the ovary Normally,
More informationInt J Clin Exp Med 2016;9(10): /ISSN: /IJCEM
Int J Clin Exp Med 2016;9(10):19935-19943 www.ijcem.com /ISSN:1940-5901/IJCEM0027833 Original Article Clinical outcome of various regimens of gonadotropin-releasing hormone analogues after conservative
More informationTreatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*
Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist
More informationLaparoscopy and Endometriosis: Preventing Complications and Improving Outcomes. Luis C. Paez M.D.
Laparoscopy and Endometriosis: Preventing Complications and Improving Outcomes Luis C. Paez M.D. Assumptions Pelvic pain Not desiring immediate fertility H & P suggest endometriosis OC/NSAID failures Endo
More informationInt J Clin Exp Med 2013;6(7): /ISSN: /IJCEM Yi Han 1,2, Shi-En Zou 1, Qi-Qi Long 1, Shao-Fen Zhang 1
Int J Clin Exp Med 2013;6(7):583-588 www.ijcem.com /ISSN:1940-5901/IJCEM1306010 Original Article The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined
More informationM0BCore Safety Profile. Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR:
M0BCore Safety Profile Active substance: Triptorelin Pharmaceutical form(s)/strength: 0,1 mg P-RMS: DE/H/PSUR/0038/002 Date of FAR: 26.05.2014 4.3 Contraindications Hypersensitivity to GnRH, its analogues
More informationPre and post surgical medical therapy. Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy
Pre and post surgical medical therapy Mauro Busacca M.D. Dept of Obstetrics and Gynecology University of Milan- Italy introduction A disease is an open problem when two conditions are nor satisfied: The
More informationA multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of
A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of Endometrioma and deep infiltrating endometriosis Professor C. Chapron and the Group
More informationImpact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles
1 st SEUD Meeting, 9 May 2015, Paris, France Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles ENDOMETRIOSIS ovarian endometrioma
More informationOrilissa (elagolix) NEW PRODUCT SLIDESHOW
Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie
More informationMYOMA of UTERUS. By Zhengyu Li M.D. GYN/OB Department West China Second Univ. Hospital, S.U.
MYOMA of UTERUS By Zhengyu Li M.D GYN/OB Department West China Second Univ. Hospital, S.U. zhengyuli@scu.edu.cn General Consideration Benign neoplasms composed primarily of smooth muscle. Most common solid
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More informationEstrogens & Antiestrogens
Estrogens & Antiestrogens Menstrual cycle... Changes and hormonal events Natural estrogens: Estadiol >> Estrone > Estriol Ineffective orally Synthesis: From cholesterol ; role of aromatase enzyme in converting
More informationWhat is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this...
PCOS What is PCOS? You'll be amazed when you read this... What is PCOS?. Who is at risk? How to get tested? What are the complications. Is there a cure? What are the right ways to eat? What lifestyle changes
More informationReduced pelvic pain in women with endometriosis: eycacy of long-term dienogest treatment
Arch Gynecol Obstet (2012) 285:167 173 DOI 10.1007/s00404-011-1941-7 GENERAL GYNECOLOGY Reduced pelvic pain in women with endometriosis: eycacy of long-term dienogest treatment Felice Petraglia Daniela
More informationunderstanding endometriosis Authored by Dr KT Subrayen Sponsored by
understanding endometriosis Authored by Dr KT Subrayen Sponsored by in this booklet What is Endometriosis? 1 What causes Endometriosis? 3 What does Endometriosis look like? 4 Common symptoms of Endometriosis
More informationLUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY*
FERTILITY AND STERILITY Copyright c 1978 The American Fertility Society Vol. 29, No.3, March 1978 Printed in U.S.A. LUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY* JAROSLA V MARIK,
More informationPrescriber and Pharmacy Guide for the Tracleer REMS Program
Prescriber and Pharmacy Guide for the Tracleer REMS Program Please see accompanying full Prescribing Information, including BOXED WARNING for hepatotoxicity and teratogenicity. Introduction to Tracleer
More informationSummary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018
JULY 2018 WHAT IS ENDOMETRIOSIS? Endometriosis is a chronic gynecological condition with symptoms that include painful menstrual periods, nonmenstrual pelvic pain, and pain during intercourse, as well
More informationEndometriosis. A Guide for Patients PATIENT INFORMATION SERIES
Endometriosis A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee.
More informationEndometriosis and Infertility - FAQs
Published on: 8 Apr 2013 Endometriosis and Infertility - FAQs Introduction The inner lining of the uterus is called the endometrium and it responds to changes that take place during a woman's monthly menstrual
More informationHistologic study of peritoneal endometriosis in infertile women
FERTILITY AND STERILITY Copyright" 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Histologic study of peritoneal endometriosis in infertile women Michelle Nisolle, M.D. Benedicte
More informationPREGNANCY AND RECURRENCE RATES IN INFERTILE PATIENTS OPERATED FOR OVARIAN ENDOMETRIOSIS
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2015 vol. 119, no. 1 SURGERY ORIGINAL PAPERS PREGNANCY AND RECURRENCE RATES IN INFERTILE PATIENTS OPERATED FOR OVARIAN ENDOMETRIOSIS Monica Holicov Luţuc 1, D. Nemescu
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationDysmenorrhoea Gynaecology د.شيماءعبداالميرالجميلي. Aetiology of secondary dysmenorrhea
30-11-2014 Gynaecology Dysmenorrhoea د.شيماءعبداالميرالجميلي Dysmenorrhoea is defined as painful menstruation. It is experienced by 45 95 per cent of women of reproductive age.primary Spasmodic Dysmenorrhea
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationA Rare Presentation of Endometriosis with Recurrent Massive Hemorrhagic Ascites which Can Mislead
Case Report INTERNATIONAL JOURNAL OF WOMEN'S HEALTH AND REPRODUCTION SCIENCES http://www.ijwhr.net A Rare Presentation of Endometriosis with Recurrent Massive Hemorrhagic Ascites which Can Mislead Article
More informationPELVIC PERITONEAL DEFECTS AND ENDOMETRIOSIS: ALLEN-MASTERS SYNDROME REVISITED
FERTU.ITY AND STERILITY Copyright " 1981 The American Fertility Society Vol. 36, No. 6, December 1981 Printed in U.S A. PELVIC PERITONEAL DEFECTS AND ENDOMETRIOSIS: ALLEN-MASTERS SYNDROME REVISITED DONALD
More informationDepartment of Obstetrics and Gynaecology, Royal Surrey County Hospital, Guildford, United Kingdom
FERTILITY AND STERILITY Vol. 62, No.4, October 1994 Copyright c 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Prospective, randomized, double-blind, controlled trial of laser
More informationCONSERVATIVE TREATMENT OF ENDOMETRIOSIS: THE EFFECTS OF LIMITED SURGERY AND HORMONAL PSEUDOPREGNANCY*t
SCIENTIFIC ARTICLES FERTILITY AND STERILITY Copyright c 1976 The American Fertility Society Vol. 27, No.7, July 1976 Printed in U.S.A. CONSERVATIVE TREATMENT OF ENDOMETRIOSIS: THE EFFECTS OF LIMITED SURGERY
More informationCNGOF Guidelines for the Management of Endometriosis
CNGOF Guidelines for the Management of Endometriosis Anatomoclinical forms of endometriosis Definitions Endometriosis is defined as the presence of endometrial tissue containing both glands and stroma
More information1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during : A systematic analysis
1 2 3 1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980 2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Injectable Fertility Medications: Bravelle, Cetrotide, Follistim AQ, Ganirelix, Gonal-F, human chorionic gonadotropin, leuprolide, Menopur, Novarel, Ovidrel, Pregnyl,
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 8/15/18 Pharmacy- Formulary 1 x Next Review: 6/18 Pharmacy- Formulary 2 x Date of Origin: 7/00 Injectable Fertility Medications: Bravelle,
More informationINFERTILITY CAUSES. Basic evaluation of the female
INFERTILITY Infertility is the inability to conceive after 12 months of unprotected intercourse. There are multiple causes of infertility and a systematic way to evaluate the condition. Let s look at some
More informationSurgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea
Page: 1 of 7 Last Review Status/Date: June 2015 for Primary and Secondary Dysmenorrhea Description Two laparoscopic surgical approaches are proposed as adjuncts to conservative surgical therapy for the
More informationGnRH agonist and antagonist: Options for endometriosis pain treatment
Thomas Jefferson University Jefferson Digital Commons Department of Obstetrics and Gynecology Faculty Papers Department of Obstetrics and Gynecology November 2006 GnRH agonist and antagonist: Options for
More informationDifference Between PCOS and Endometriosis
Difference Between PCOS and Endometriosis www.differencebetween.com Key Difference PCOS vs Endometriosis Ovaries play an important role in the reproduction and the maintenance of the female body. They
More informationSurgical treatment of endometriosis: location and patterns of disease at reoperation
Surgical treatment of endometriosis: location and patterns of disease at reoperation Elizabeth Taylor, M.D., and Christina Williams, M.D. Division of Reproductive Endocrinology and Infertility, Department
More informationThe pharmacological management of ENDOMETRIOSIS
The pharmacological management of ENDOMETRIOSIS 18 Endometriosis is a gynaecological condition in which endometrial tissue is present outside the uterine cavity, causing cyclic symptoms and, often, reduced
More informationModern Management of Fibroids
Modern Management of Fibroids Mr Narendra Pisal The Portland Hospital Fibroids Very common 20-40% of all women Up to 80% of black women by 50y Most fibroids are asymptomatic 50% will have significant symptoms
More informationWestern Locality Shared care information ~ Gonadorelin Analogues (Gnrh)
Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh) Specialist: Please complete the Shared Care letter sending a request to GP (see bottom of the page) April 2013 GP: Please indicate
More informationPrescriber and Pharmacy Guide for the Opsumit REMS Program
Prescriber and Pharmacy Guide for the Opsumit REMS Program (Risk Evaluation and Mitigation Strategy) including BOXED WARNING for teratogenicity. Risk of teratogenicity Introduction to Opsumit (macitentan)
More informationChronic Pelvic Pain. Bridget Kamen, MD Obstetrics and Gynecology, Confluence Health. I have no disclosures
Chronic Pelvic Pain Bridget Kamen, MD Obstetrics and Gynecology, Confluence Health I have no disclosures Objectives A little epidemiology Understand there are both gynecologic and non-gynecologic causes
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More informationDienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis
doi:10.1111/jog.13023 J. Obstet. Gynaecol. Res. Vol. 42, No. 9: 1152 1158, September 2016 Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis Yotaro
More informationInfertility DR. RAHUL BEVARA
Infertility DR. RAHUL BEVARA Definitions Infertility is defined as the inability to conceive after one year of unprotected coitus. Affects 10-15% of couples Primary Infertility, that is inability to conceive
More informationPrescriber Guide for the Letairis REMS Program
LETAIRIS RISK EVALUATION AND MITIGATION STRATEGY (REMS) Prescriber Guide for the Letairis REMS Program Changes to the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program (November 2018) Revised:
More informationEndometriosis. A Guide for Patients PATIENT INFORMATION SERIES
Endometriosis A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee.
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationHenk R. Franke, M.D., Ph.D., a Peter H. M. van de Weijer, M.D., Ph.D., b Ton M. M. Pennings, M.D., c and Marius J. van der Mooren, M.D., Ph.D.
FERTILITY AND STERILITY VOL. 74, NO. 3, SEPTEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Gonadotropin-releasing
More informationENDOMETRIOSIS. Bladder endometriosis must be considered as bladder adenomyosis MATERIALS AND METHODS
FERTILITY AND STERILITY VOL. 74, NO. 6, DECEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. ENDOMETRIOSIS Bladder
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationDrug Class Monograph
Drug Class Monograph Class: Gonadotropin Releasing Hormone (GnRH) Analogs Drugs: Eligard (leuprolide acetate), Firmagon (degarelix), Lupaneta Pack (leuprolide acetate and norethindrone), Lupron Depot (leuprolide
More informationEndometriosis - MRI findings with anatomic-pathologic correlation
Endometriosis - MRI findings with anatomic-pathologic correlation Poster No.: C-2551 Congress: ECR 2015 Type: Educational Exhibit Authors: E. Matos, A. T. Almeida, A. Sanches; Vila Nova de Gaia/PT Keywords:
More informationStudy No.: Title: Rationale: Phase Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSaint Mary s Hospital. Gynaecology Unit. Saint Mary s Hospital. Endometriosis. Information For Patients
Saint Mary s Hospital Gynaecology Unit Saint Mary s Hospital Endometriosis Information For Patients Contents What is endometriosis?... 3 What happens?... 3 Who is affected?... 3 Outlook... 3 What are the
More informationDrug Class Update: Drugs for Endometriosis
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal myomectomy in leiomyoma management, 77 Abnormal uterine bleeding (AUB) described, 103 105 normal menstrual bleeding vs., 104
More informationD-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas
FERTILITY AND STERILITY Copyright" '1989 The American Fertility Society Vol. 52, No.3, Septemher 1989 Printed on acid-free paper in U.S.A. D-Trp-6-luteinizing hormone-releasing hormone microcapsules in
More informationCLEAR COVERAGE HYSTERECTOMY CHECKLISTS
CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines
More informationInvestigations and management of severe endometriosis
Investigations and management of severe endometriosis Dr Jim Tsaltas Head of Gynaecological Endoscopy and Endometriosis Surgery Monash Health Monash University Dept of O&G Melbourne IVF Freemasons Hospital
More informationSOUTH AFRICAN GUIDELINE FOR TREATMENT OF ENDOMETRIOSIS
SOUTH AFRICAN GUIDELINE FOR TREATMENT OF ENDOMETRIOSIS SASREG PUBLICATION Recommended treatment protocols for the South African patient population based on the European Society of Human Reproduction and
More informationPublic Statement: Medical Policy Statement: Background:
ARBenefits Approval: 10/12/2011 Effective Date: 01/01/2012 Revision Date: Code(s): 58578, unlisted laparoscopy procedure, uterus Medical Policy Title: Surgical Interruption of Pelvic Nerve Pathways for
More informationDr Mary Birdsall. Fertility Associates Auckland
Dr Mary Birdsall Fertility Associates Auckland Period Problems Mary Birdsall Medical Director Fertility Associates Auckland Period Problems Basic Physiology No Periods Irregular Periods Heavy Periods
More informationPremature Menopause : Diagnosis and Management
Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges
More informationEndometriosis Samuel J. Chantilis, M.D.
Endometriosis Samuel J. Chantilis, M.D. I. INTRODUCTION Endometriosis is the presence and growth of glands and stroma identical to the lining of the uterus in an aberrant location. Common symptoms of endometriosis
More informationPrognostic factors of ovarian response and IVF outcome in patients with deep infiltrating endometriosis Claire GAUCHE-CAZALIS, Chadi YAZBECK
Prognostic factors of ovarian response and IVF outcome in patients with deep infiltrating endometriosis Claire GAUCHE-CAZALIS, Chadi YAZBECK Obstetrics Gynecology and Reproductive Medicine Department Bichat
More informationMedication Prior Authorization Form
Policy Number: 1047 Eligard (leuprolide acetate) 7.5mg Eligard (leuprolide acetate) 22.5mg Eligard (leuprolide acetate) 30mg Eligard (leuprolide acetate)45mg Firmagon (degarelix) Lupaneta Pack (leuprolide
More informationEndometriosis: treatment with gonadotropinreleasing hormone agonist Buserelin*t
FERTILITY AND STERILITY Copyright 989 The American Fertility Society Printed in U.S.A. Endometriosis: treatment with gonadotropinreleasing hormone agonist Buserelin*t Anton M. H. W. Franssen, M.D.:j: Frank
More informationNEW TREATMENTS FOR OVARIAN ENDOMETRIOMA
SEUD 2018 NEW TREATMENTS FOR OVARIAN ENDOMETRIOMA Ivo Brosens Giuseppe Benagiano Faculty of Medicine, KU Leuven, Belgium Sapienza University, Rome, Italy Hughesdon P.E. (1957) THE OVARIAN ENDOMETRIOMA
More informationDoes Helica treatment of early endometriosis confer short- and long-term benefits in terms of pain relief and sub-fertility?
Gynecol Surg (2013) 10:213 217 DOI 10.1007/s10397-013-0803-7 ORIGINAL ARTICLE Does Helica treatment of early endometriosis confer short- and long-term benefits in terms of pain relief and sub-fertility?
More informationThe Association of Minimally Invasive Gynecologic Surgeons dedicated to safe, state-of-the-art surgery and health life-styles for women of all ages
The Association of Minimally Invasive Gynecologic Surgeons dedicated to safe, state-of-the-art surgery and health life-styles for women of all ages R. Wayne Whitted MD, MPH Paul A. Pietro MD Marina Santana
More informationOvarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy
Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationMedical Management of Endometriosis: Novel Targets and Future Treatments Erkut Attar, M.D. PhD.
Medical Management of Endometriosis: Novel Targets and Future Treatments Erkut Attar, M.D. PhD. Istanbul University Istanbul Medical School Department of Obstetrics & Gynecology Division of Reproductive
More information